Peter Hillmen
彼得·希尔曼
MB ChB, PhD, FRCPath
Professor of Experimental Haematology; Consultant Haematologist, Leeds Teaching Hospitals实验血液学教授兼利兹教学医院血液科顾问
👥Biography 个人简介
Prof. Peter Hillmen is one of the UK's foremost CLL researchers, best known for leading the FLAIR trial comparing ibrutinib-based regimens to chemoimmunotherapy. His work has been central to establishing modern frontline CLL treatment standards in Europe and globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FLAIR Trial and Frontline CLL Therapy
Led the UK FLAIR trial, a multi-arm randomized study demonstrating ibrutinib plus rituximab and ibrutinib plus venetoclax superiority over standard FCR chemoimmunotherapy in frontline CLL, informing national guidelines.
PNH and CLL Complement-Targeted Therapy
Contributed landmark studies on complement inhibition in PNH and studied novel therapeutic pathways in CLL, bridging translational insights from rare hematologic diseases to lymphoid malignancies.
Representative Works 代表性著作
Ibrutinib plus Venetoclax versus Fludarabine, Cyclophosphamide, and Rituximab in Patients with Previously Untreated CLL (FLAIR)
New England Journal of Medicine (2023)
FLAIR trial showing ibrutinib-venetoclax doublet achieves superior MRD-negative rates and PFS versus FCR in frontline CLL.
Rituximab plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared to Fludarabine and Cyclophosphamide Alone in Previously Treated CLL
Blood (2014)
UK-CLL4 trial follow-up establishing chemoimmunotherapy benchmarks for subsequent targeted therapy comparisons.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 彼得·希尔曼 的研究动态
Follow Peter Hillmen's research updates
留下邮箱，当我们发布与 Peter Hillmen（University of Leeds）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment